Medicare's GLP-1 Bridge Program launches July 1, 2026 — 21 days from now — covering brand Wegovy (injection and tablets), Zepbound KwikPen, and Foundayo at a flat $50/month copay through December 31, 2027. But the eligibility tiers are stricter than most coverage headlines suggest, and you cannot enroll yourself — your prescriber submits a prior authorization through Medicare's central processor. If you fall in the eligibility gap (BMI 27-35 without a qualifying condition), the cheapest legitimate alternatives are compounded programs from Embody at $99/month, Yucca Health at $146/month, or our Editor's Choice TrimRx at $199/month. Here's the full eligibility breakdown, the exact enrollment steps to start this week, and the fallback plan if you don't qualify.
Does Medicare cover GLP-1 for weight loss?
Yes — starting July 1, 2026. For the first time, Medicare will cover GLP-1 medications prescribed for obesity (not just diabetes) through the GLP-1 Bridge Program, a CMS demonstration running July 1, 2026 through December 31, 2027. Covered beneficiaries pay a flat $50/month copay.
Before July 1, Medicare Part D covers GLP-1s only for type 2 diabetes (Ozempic, Mounjaro) or cardiovascular risk reduction (Wegovy, for patients with established heart disease). Weight loss alone has never been a covered indication — until now.
What GLP-1 medications does Medicare cover under the Bridge Program?
| Medication | Form | Bridge copay | |---|---|---| | Wegovy (semaglutide) | Weekly injection + daily tablets | $50/month | | Zepbound KwikPen (tirzepatide) | Weekly injection | $50/month | | Foundayo (orforglipron) | Daily oral pill | $50/month |
Compounded semaglutide and compounded tirzepatide are not covered — the Bridge Program covers FDA-approved brand products only.
Who qualifies: the 3 eligibility tiers
This is where most headlines get it wrong. The Bridge Program is not "BMI 30+ gets $50 Wegovy." CMS set three tiers, and each requires specific chart documentation:
Tier 1 — BMI ≥35. No additional conditions required. If your documented BMI is 35 or higher and you're enrolled in Medicare Part D, you qualify.
Tier 2 — BMI ≥30 plus one of: - Heart failure - Uncontrolled hypertension - Chronic kidney disease (CKD)
Tier 3 — BMI ≥27 plus one of: - Prediabetes (A1C 5.7-6.4) - Prior heart attack (MI) - Prior stroke - Peripheral artery disease (PAD)
Also required for all tiers: - Enrolled in Medicare Part D (standalone plan or Medicare Advantage with drug coverage) - BMI and qualifying condition documented in your medical record - Prescription from a Medicare-enrolled prescriber
Two costly fine-print details (per KFF's analysis of the BALANCE model): the $50 copay does not count toward your $2,100 annual Part D out-of-pocket cap, and Extra Help (Low-Income Subsidy) cannot be applied to reduce it. The $50 is the floor for everyone.
How to enroll: your doctor submits, not you
There is no enrollment website, no application form, and no phone line where you can sign yourself up. Per CMS's beneficiary guidance, the flow runs entirely through your prescriber:
Step 1 (this week) — Book a visit with a Medicare-enrolled prescriber. Primary care is fine. The goal: get your BMI measured and recorded, and your qualifying condition (if Tier 2/3) documented with a current diagnosis code.
Step 2 — Your prescriber submits a prior authorization to CMS's contracted central processor (administered by Humana) along with the prescription. They can begin submitting now, ahead of the July 1 start.
Step 3 — Approval and fill. Once approved, you fill the prescription at a participating pharmacy and pay $50. Refills continue at $50/month through December 31, 2027 while you remain eligible.
Why act this week, not July: prior authorizations queue. CMS published provider instructions in its June 4 MLN Connects bulletin, which means prescribers nationwide are submitting right now. A documented-and-submitted file on June 15 fills in early July; starting the process on July 1 could mean an August fill.
If your BMI or A1C isn't documented yet: that primary care visit is the unlock. A BMI measurement takes one appointment. An A1C of 5.7-6.4 (prediabetes — roughly 1 in 3 US adults over 65) immediately qualifies a BMI-27+ patient under Tier 3.
The eligibility gap: who's left out
Run the tiers against real patients and a large group falls through:
- BMI 27-29.9 with no prediabetes or cardiovascular history — not eligible
- BMI 30-34.9 with "only" controlled hypertension, sleep apnea, or high cholesterol — not eligible (those conditions don't count; uncontrolled hypertension, HF, and CKD do)
- Medicare Advantage without Part D drug coverage — not eligible
- Not on Medicare at all (under 65, no disability pathway) — not eligible
If you're in the gap, your realistic alternatives in June 2026:
- Embody — $99/month. The cheapest credentialed compounded GLP-1 program we track. HSA/FSA eligible.
- Yucca Health — $146/month on a 6-month plan. The best price-to-credentialing balance; Klarna/Affirm financing.
- TrimRx — $199/month (Editor's Choice). Flat all-inclusive pricing at every dose, LegitScript-listed pharmacy.
- MyStart Health — $224/month with code SELFLOVE25. Unlimited clinician access and labs included — useful if you want A1C testing that might later qualify you for Tier 3.
- MEDVi — $179 first month. Lowest entry point for trialing.
- SkinnyRx — $199/month. No commitment, flat pricing.
- NovoCare cash-pay — $249/month for brand Wegovy direct from Novo Nordisk, no eligibility requirements beyond standard BMI criteria.
For the full comparison see our cheapest compounded semaglutide ranking and cheapest GLP-1 programs page.
Bridge Program vs. your current option: the math
| Your situation | Best path | Monthly cost | |---|---|---| | Part D + BMI ≥35 | Bridge Program | $50 | | Part D + BMI 30+ with HF/CKD/uncontrolled HTN | Bridge Program | $50 | | Part D + BMI 27+ with prediabetes or prior MI/stroke | Bridge Program | $50 | | Part D + BMI 27-34.9, no qualifying condition | Compounded (Embody) | $99 | | Medicare Advantage, no Part D | Compounded or NovoCare | $99-$249 | | Not on Medicare, paying Wegovy cash | See our Wegovy cheaper guide | $25-$249 |
One nuance for gap patients currently paying $99-$199 for compounded: getting a prediabetes diagnosis changes your tier. If your BMI is 27+ and you've never had an A1C drawn, a single blood test could move you from $99-$199 compounded to $50 brand Wegovy. Ask for an A1C at your next visit before assuming you're stuck in the gap.
Will the Bridge Program last?
It's a demonstration, funded through December 31, 2027. CMS will evaluate cost and outcomes data to decide whether GLP-1 coverage for obesity becomes a permanent Part D benefit. Two scenarios for 2028:
1. Made permanent — likely with refined eligibility and possibly higher cost-sharing. 2. Allowed to lapse — beneficiaries revert to diabetes-and-cardiovascular-only coverage, and the self-pay market (compounded, NovoCare, Foundayo's $149 launch pricing) becomes the fallback again.
Either way, the 18-month window is real. If you qualify, use it — the cardiovascular and kidney benefits of staying on a GLP-1 compound over time (see our 90,000-patient long-term analysis), and $50/month is the cheapest legitimate GLP-1 access ever offered to seniors.
FAQ
Can I enroll in the Bridge Program myself? No. Your prescriber submits the prior authorization and prescription through CMS's central processor (administered by Humana). Your job is the doctor's visit and the documentation.
Does the Bridge Program cover Ozempic or Mounjaro? No — those remain covered under standard Part D for type 2 diabetes only. The Bridge Program covers Wegovy, Zepbound KwikPen, and Foundayo for weight management.
Does the $50 count toward my Part D out-of-pocket cap? No. The $50/month Bridge copay sits outside the $2,100 annual cap, and Extra Help subsidies don't apply to it.
I have Medicare Advantage. Am I eligible? Only if your plan includes Part D drug coverage (most MA-PD plans do). MA-only plans without drug coverage don't qualify.
My BMI is 31 and I have sleep apnea — do I qualify? Not under current tiers. Sleep apnea is not a Tier 2 qualifying condition (heart failure, uncontrolled hypertension, CKD). Check whether you have prediabetes (A1C 5.7+) — at BMI 27+, that qualifies you under Tier 3.
What happens December 31, 2027? The demonstration ends. CMS decides whether to make coverage permanent based on the demonstration's cost and outcomes data. Nothing is guaranteed past that date.
Is compounded semaglutide covered? No. Brand FDA-approved products only. If you don't qualify for the Bridge, compounded remains the cheapest legitimate path at $99-$224/month — see our compounded semaglutide ranking.
For complete Medicare GLP-1 coverage details including the CMS BALANCE model background, see our Medicare GLP-1 coverage guide. For state Medicaid coverage, see the insurance coverage hub.